Outlook Therapeutics is trading at $0.60, up 5.38%, as of 10:29 a.m. on October 7, 2026; available evidence does not identify a clear catalyst for the gain.
- No new company announcement for October 7 appears in the company’s press-release archive; its latest listed release is the October 1 J-code application update.
- Broader markets and biotech were under pressure, a backdrop that does not explain the stock’s move higher.